Spring direct naar de hoofdnavigatie of de inhoud
‘There may be more to an invention than meets the eye. By recording the invention in a patent application, this added value comes into its own.’
Raygene Martier

Raygene Martier

  • Life Sciences
  • Trainee Patent Attorney

Raygene Martier studied  Biomolecular Sciences  at VU Amsterdam with majors in molecular biology and  biochemistry. He gained work experience in both academia and industry.

Continue reading

He  has extended his  knowledge in areas such as gene therapy, neurology,  virology, microbiology, immunology, biochemistry, molecular biology, cell biology, diagnostics and medical biotechnology. He started his PhD in 2015 at the gene therapy company uniQure,  where he was responsible for development of RNAi-based gene therapies for differed neurodegenerative disorders. Here he also had the opportunity to support the IP department and became aware that R&D and IP go hand in hand.

Raygene  joined V.O. in 2019 as trainee patent attorney. He enjoys  being at the interface between science and Patent Law.


  • PhD in RNAi-based gene therapies for  neurodegenerative disorders, Leiden U niversity/uniQure (2020)
  • MSc in Biomolecular Sciences, VU Amsterdam (2013)
  • BSc in Biotechnologie, Noordelijke Hogeschool Leeuwarden (2009)


  • Martier R, Liefhebber JM, Miniarikova J, van der Zon T, Snapper J, Kolder I, Konstantinova P. (2019). Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients. Mol. Ther. Nucleic. Acids.14: 593-608.
  • Martier R, Liefhebber JM, Garcia-Osta A, Miniarikova J, Cuadrado-Tejedor M, Espelosin M, Konstantinova P. (2019). Targeting RNA-Mediated toxicity in C9orf72 ALS and/or FTD by RNAi-Based gene Therapy. Mol. Ther. Nucleic. Acids.16: 26-37
  • Martier R, Sogorb Gonzalez M, Stricker-Shaver J, Hübener-Schmid J, Keskin S, Witjas J, van Deventer SJ, Konstantinova P, Phuc Nguyen H, Evers MM. (2019). Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease. Mol. Ther. Methods & Clinical Development Acids. https://doi.org/10.1016/j.omtm.2019.10.008.
  • Pietersz KL, Martier R, Baatje SM, Liefhebber JM, Brouwers CC, Pouw SM, Fokkert L, Lubelski J, Petry H, Martens GJM, van Deventer SJ, Konstantinova P, Blits B. (2019). Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery. Gene Ther. Under submission.
  • Liefhebber, J., Martier, R., Van der Zon, T., Keskin, S., Huseinovic, A., Lubelski, J., Blits, B., Petry, H., Konstantinova, P. (2019) In depth characterization of a Mifepristone regulated expression system for AAV5-mediated gene therapy in the liver. Mol. Ther. Methods & Clinical Development.13: 512-525.
  • Keskin S, Brouwers CC, Sogorb-Gonzalez M, Martier R, Depla JA, Vallès A, van Deventer SJ, Konstantinova P, Evers MM. (2019) AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patientderived neuronal cultures and astrocytes. Mol. Ther: Methods & Clinical Development. doi: https://doi.org/10.1016/j.omtm.2019.09.010.
  • Miniarikova J, Zimmer V, Martier R, Brouwers C. C, Pythoud C, Richetin K, Konstantinova P. (2017). AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 24: 630-639.
  • Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Konstantinova P. (2016). Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington’s Disease. Mol. Ther. Nucleic Acids: e297.
  • MacZuga P, Verheij J, Van Der Loos C, Van Logtenstein R, Hooijer G, Martier R, Konstantinova P. (2014). Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. Gene. Ther. 21: 60-70.
  • Staszewski O, Baker RE, Ucher AJ, Martier R, Stavnezer J, Guikema JEJ. (2011). Activation-Induced Cytidine Deaminase Induces Reproducible DNA Breaks at Many Non-Ig Loci in Activated B Cells. Molecular Cell. 41(2): 232-242.


  • Dutch
  • English
  • Spanish
  • Papiamento

Also see these experts

Hajo Kraak

Hajo Kraak

  • European and Dutch Patent Attorney
  • Partner
Frits Michiels

Frits Michiels

  • European and Dutch Patent Attorney
  • Senior Associate
More experts



“Prevention is better than cure.” That is highly applicable to the invention of vaccinations. Thanks to immunization, we can control diseases such as smallpox, polio and measles.  Across the globe, we are currently hoping that a vaccine against the coronavirus SARS-CoV-2 will be developed soon.Continue reading

COVID-19 update 6

The government measures to combat COVID-19 not only affect business operations but they could also impact you as a patent applicant or patent holder.Continue reading

COVID-19: statutory patent terms can’t simply be adjusted for no reason

The government measures to combat COVID-19 not only affect business operations but they could also impact you as a patent applicant or patent holder.Continue reading


Chemport Connect – Biobased & Circular Polymers 2020

The first edition of Chemport Connect - Biobased & Circular Polymers (previously announced as the Sustainable Plastics & Materials Expo 2020) will take place digitally on 17 November 2020. Continue reading

IP Service World 2020

Holiday Inn Munich - City Centre, Hochstraße, München, Germany

Europe’s largest IP Convention & Trade Fair, the IP Service World, is a very unique event. It is the perfect mixture of a comprehensive trade fair and a top-class convention with contributions from leading experts. Continue reading

Dutch Life Sciences Conference 2020

CORPUS Congress Centre, Willem Einthovenstraat 1, 2342 BH Oegstgeest, The Netherlands

The foremost life sciences business network event in the Netherlands With more than 450 life sciences companies the Dutch Life Sciences sector has doubled in size during the last decades. Continue reading